Get the Stockscreener App
2.26
1.74%
-0.04
After Hours:
2.27
0.01
+0.44%
Tharimmune Inc stock is traded at $2.26, with a volume of 36,481.
It is down -1.74% in the last 24 hours and up +15.90% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.30
Open:
$2.39
24h Volume:
36,481
Relative Volume:
0.03
Market Cap:
$3.42M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-3.1389
EPS:
-0.72
Net Cash Flow:
$-7.30M
1W Performance:
-9.60%
1M Performance:
+15.90%
6M Performance:
-50.58%
1Y Performance:
-95.71%
1-Day Range:
$2.26
$2.41
1-Week Range:
$2.26
$2.73
52-Week Range:
$1.835
$16.20
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
2.26 | 3.42M | 0 | -9.32M | -7.30M | -0.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Tharimmune Inc Stock (THAR) Latest News
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 - AccessWire
Tharimmune appoints new board member, cancels Intract merger By Investing.com - Investing.com South Africa
Tharimmune appoints new board member, cancels Intract merger - Investing.com
Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch
Penn State wins trademark case over retailer's use of vintage logos, images - Corsicana Daily Sun
Oil company Phillips 66 faces federal charges related to alleged Clean Water Act violations - Corsicana Daily Sun
Valsoft Corporation Enters the Book Industry Software Space with the Acquisition of Edelweiss - Corsicana Daily Sun
Travelers Capital and TCC Financial Bolster Investor Relations Service, Compliance, and Growth with the Appointment of Mark Breakspear - Corsicana Daily Sun
Oleria Named a Winner in Fast Company's 2024 Next Big Things in Tech Awards - Corsicana Daily Sun
Congratulations to Tenorshare for Winning French Design Award - Corsicana Daily Sun
LQR House Inc. Board of Directors Approves Purchase of Up to $1M Bitcoin as Treasury Reserve Asset and Retention of Up to $10M Crypto Payments on CWSpirits.com - Corsicana Daily Sun
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Corsicana Daily Sun
Sterling Metals Completes 3D IP Survey at Copper Road, Discovers New Outcrop Areas and Extends Mineralized Footprint - Corsicana Daily Sun
BofA Strengthens Support for Arizona Entrepreneurs through State’s Largest Supplier Diversity Program Impact AZ - Corsicana Daily Sun
Diversified Announces Upcoming Investor Engagement - Corsicana Daily Sun
What's Going On With Tharimmune Shares Monday? - Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts
Tharimmune's Liver Drug Shows 33% Itch Reduction in Phase 1 Trial, Phase 2 Planned | THAR Stock News - StockTitan
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada
Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com Canada
What's Going On With Tharimmune Shares Wednesday? - MSN
Tharimmune set to receive European patent for cancer therapy tech - Investing.com
Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan
GC Football: Player of the Week - Corsicana Daily Sun
Hoverfly Technologies Promotes Steve Topping to Chief Operating Officer - Corsicana Daily Sun
Tharimmune Announces Upcoming Conference Presentations - StockTitan
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN
New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
S&P 500 Total Return (TCU24) Quote - The Globe and Mail
Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR
Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph
Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks
Tharimmune secures EMA feedback on pruritus drug trial - Investing.com
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan
TH104 trial shows promise for liver disease-related itch relief By Investing.com - Investing.com South Africa
TH104 trial shows promise for liver disease-related itch relief - Investing.com
Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - TipRanks
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Milton Daily Standard
Tharimmune CEO Randy Milby buys $5.2k in company stock - Investing.com India
Tharimmune CEO Randy Milby buys $5.2k in company stock By Investing.com - Investing.com Australia
Tharimmune COO acquires $9,650 in company stock - Investing.com
Tharimmune COO acquires $9,650 in company stock By Investing.com - Investing.com UK
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):